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doi:10.1016/j.ejvs.2009.01.009Abstract Daily low-dose acetylsalicylacid (ASA) is prescribed to patients with atherothrom-
bosis frequently to prevent vascular complications. In reports on complications and side
effects of low-dose ASA use in the literature there is a range of definitions. We explored the
incidence, characteristics and consequences of symptoms suggestive of ASA intolerance in
patients on low-dose ASA.
General practitioners and specialists in 105 centres were asked to review their patient files
for the last 10 consecutive patients who were prescribed ASA. Participating patients completed
a questionnaire about their current ASA use (doctors completed the questionnaire together
with the patients), use of co-medication and symptoms suggestive of ASA intolerance.
A total of 947 patients were included in this study. Sixty patients (6.6%) had ceased ASA
treatment, predominantly because of the occurrence of side effects suspected to be caused
by ASA use. A quarter of the patients concomitantly used an anti-acid agent. Of the 947
patients, 271 (30.6%) indicated symptoms during ASA intake. The most common symptoms
were related to the gastrointestinal tract (25.1%).
In patients prescribed a low-dose of ASA monotherapy, side effects suggestive of intolerance
are common. More awareness should be created to detect and treat these symptoms, because
the occurrence of side effects is the most important reason for patients to discontinue ASA
treatment.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.7556965; fax: þ31 88 7555017.
ht.nl (F.L. Moll).
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598 E. Tournoij et al.The benefits of acetylsalicylacid (ASA) in the prevention of
atherothrombosis have been well described in literature.1
However, little is knownabout the incidenceof symptomsand
side effects of low-dose ASA use. Different studies have
studied theefficacy andadverseeffects ofASA, but haveused
a higher dose of ASA2,3 or reported only bleeding complica-
tions.4,5 In a studyby Silagy et al.,6 theadverse effects of low-
dose aspirin (100 mg daily) were studied in the elderly
without pre-existing major vascular diseases in a double-
blind, randomised, placeboecontrolled trial. Gastrointes-
tinal symptoms were reported by 18% of participants
receiving aspirin (compared to 13% in the placebo group).
Clinically evident gastrointestinal bleeding occurred in 3% of
subjects receiving aspirin and none receiving placebo.
Definitions used for this phenomenon are: hypersensi-
tivity, allergy, intolerance and interaction. Studies have
estimated the prevalence between 5% and 36% depending
on the definition used.7,8 Signs and symptoms of intolerance
include dyspepsia and allergic rhinitis and more serious side
effects such as gastric haemorrhage and/or perforation,
bronchospasm and the exacerbation of asthma.9,10 The
onset of side effects varies from days (skin rash) to months
or even years (asthma or dyspepsia) after initiation of ASAFigure 1 Profiletherapy. Discontinuation of ASA therapy is associated with
an increased risk of atherothrombotic complications.11 In
contrast to patients on a high dosage of ASA, the associa-
tion between symptoms and the low dose of ASA might be
underestimated by both patients and doctors.
We performed an observational study to estimate the
prevalence of ASA intolerance in patients with a low-dose
(120 mg) ASA monotherapy. The secondary goals of this
study were to examine the signs and symptoms experienced
by ASA-intolerant patients, the severity and duration of these
signs and symptoms and the consequences. To investigate
this in a large population, we approached patients over 40
years of age in 105 outpatient practices of either vascular
surgeons, neurologists, internists or general practitioners.Material and methods
From December 2006 to January 2008, investigators
(vascular surgeons, neurologists, internists or general
practitioners) in 105 centres in the Netherlands were asked
to search their patients’ files for the last 10 patients known
to be prescribed low-dose ASA (Fig. 1). Ten consecutiveof the study.
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exclusion criteria. The consecutive method was chosen to
prevent patient selection bias. Patients were invited to visit
the clinic, during which visit the doctor interviewed the
patient and completed the questionnaire. The start date of
ASA use was documented. The doctor could include both
chronic and recent users of ASA. Only patients who were
already prescribed ASA treatment according to their files
were included, which means that only those patients were
included of which the participating doctors were convinced
that they could tolerate ASA at the start of prescription.
Inclusion and exclusion criteria
Inclusion criteria for study participation were: (1) age over
40 years and (2) use of ASA or carbasalate calcium in
a dosage of 30e120 mg per day. Patients were excluded
from the study if ASA or carbasalate calcium was used in
combination with other platelet aggregation inhibitors such
as clopidogrel or dipyridamole.
ASA use
Information about duration of ASA use and daily dosage was
obtained. Patients were asked if they were still taking ASA.
If not, the reason to discontinue ASA treatment was
obtained (from the following options): occurrence of side
effects; increase of complaints; no effect of treatment;
unclear necessity for ASA use; patient thinks ASA use is not
required and other reasons to cease ASA use.
Contraindications for ASA use
The contraindications screened were: history of stomach
problems or symptoms of stomach ache after previous ASA
intake; history of peptic ulcer disease or gastrointestinal
bleeding; allergy to salicylic acid or prostaglandin synthesis
inhibitors; severe renal or hepatic insufficiency; history of
haemorrhagic diathesis or coagulopathy.
Use of other medication
The use of co-medication was screened for the following
drugs: antacids, oral anticoagulants and non-steroidal anti-
inflammatory drugs (NSAID).
General symptoms
Patients were asked for adverse effects during the full
period of ASA use. When answered ‘yes’, these were
further characterised by the following categories: symp-
toms of the upper respiratory tract, symptoms of blood and
lymphoid system, skin or immune system and symptoms of
the gastrointestinal tract.
Symptoms of the upper respiratory tract
Patients were screened for the existence of symptoms of
the upper respiratory tract: nose bleedings; rhinitis; bron-
chospasms; asthma and other symptoms of the upperrespiratory tract. If present, these symptoms were further
characterised by duration, course and intensity.
Symptoms of the blood and lymphoid system, skin
or immune system
Patients were screened for the existence of symptoms in
blood and lymphoid system (thrombocytopaenia and
anaemia), skin (rash and urticaria) and immune system
(e.g., angio-oedema and allergy). Occurrence of thrombo-
cytopaenia was documented.
Symptoms of the gastrointestinal tract
Patients were screened for the following gastrointestinal
symptoms: epigastric discomfort; epigastric pain; vomiting;
constipation; diarrhoea; gastrointestinal bleeding; gastric/
duodenal ulcer; epigastric burning/reflux; gastritis and
other symptoms of the gastrointestinal tract.
To document these symptoms a questionnaire based on
the ROME II criteria (Research Diagnostics Questions for
functional gastrointestinal disorders) was used.12 The
questions in this list quantify the severity of the complaint
by measuring the period and intensity of its occurrence.
Ethical considerations
The study did not necessitate any extra medical interven-
tions. The investigators maintained all freedom to
prescribe medication. No ethical approval of this study was
needed according to Dutch law as subjects were not
submitted to changes in medications or interventions. The
data were collected anonymously. To protect the patient’s
privacy, only the year of birth was documented and
a unique study number was assigned to the patient. The
documented data can only be traced to the medical source
data by the patients’ own doctor.
Data analysis
Data are presented by descriptive statistics, consisting of
means with standard deviation, median and range for
continuous variables and numbers and percentages for
categorical variables.
Results
Patient characteristics
Table 1 shows the baseline characteristics of the study
population. The study included 957 patients from 105
centres. Although we chose the combination of ASA with
another platelet aggregation inhibitor such as clopidogrel
of dipyridamole as an exclusion criterion, 10 patients (1.1%)
did not use ASA as monotherapy and were excluded from
the analysis, which resulted in a total inclusion of 947
patients. The mean age of the patients was 68.3 years.
More males than females were included (59.6% vs. 40.4%,
respectively). The median ASA dosage used was 100 mg per
day (range: 30e120 mg per day), for an average of 5.07
Table 1 Baseline characteristics and contraindications of
ASA
Baseline characteristics %
Age (years) 68.3 a(11.19)
Male (%) 59.6
Female (%) 40.4
Median dosage of ASA
(mg per day)
100 b(30e120)
Mean duration of ASA
use (mean (2) SD? years)
5.07 a(5.2)
Contraindications %
History of frequent stomach
upset or gastric pain after
previous ASA intake
13.7% c(129/942)
History of peptic ulcer disease
or gastrointestinal bleeding
7.1% c(67/942)
Allergy to salicylic acid or
prostaglandin
synthesis inhibitors
1.0% c(9/942)
Severe renal or hepatic
insufficiency
2.0% c(19/939)
History of haemorragic diathesis
or coagulopathy
0.1% c(1/942)
a (SD).
b Range.
c Number of patients with contraindications/total number of
patients (nZ 947) minus the missing patients.
Table 2 Symptoms of ASA intolerance per category
Symptoms % n
Upper respiratory tract 9.4% 89
Nose bleeding 21% 19
Rhinitis 13% 12
Bronchospasm 15% 14
Asthma 23% 21
Other 39% 35
Blood and lymph 4.4% 42
Thrombocytopaenia 5% 2
Anaemia 40% 17
Other 55% 23
Skin 8.3% 79
Rash 34% 27
Urticaria 25% 20
Other 41% 32
Immune system 0.7% 7
Angio-oedema 43% 3
Other 57% 4
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ASA, according to their file, appeared to have stopped using
ASA, mostly because of occurrence of side effects (52%).
Other reasons to cease ASA intake were increase of
complaints (10%), no effect (3%), unclear necessity for ASA
use (3%), the patient assumed ASA use is not required (3%)
and other reasons to stop ASA (18%). Of these patients, 65%
(39/60) terminated ASA use after 30 days.
Contraindications of ASA and co-medication
The six questions considering contraindications of ASA use
indicated that 13.7% of the patients reported a history of
pain in the stomach region (Table 1). Other contraindica-
tions to ASA, such as allergy to salicylic acid or prosta-
glandin synthesis inhibitors, severe kidney or liver
insufficiency, intake of other platelet aggregation inhibitors
and history of haemorrhagic diathesis or coagulopathy were
uncommon. However, 7.1% of patients had a history of
peptic ulcer disease or gastrointestinal bleeding. A quarter
of the patients using daily low-dose ASA concomitantly used
an anti-acid agent. Concomitant use of oral anticoagulants
occurred in 5.2% of patients and/or use of other NSAID
occurred in 6.6% of patients.
Occurrence of side effects
Over 30% of the included patients using ASA indicated the
occurrence of side effects to the investigator. Twenty-nine
patients (3.1%) experienced severe side effects. Thesewere defined by the highest scores on the questionnaire
considering astmatic (severe) or gastrointestinal (severe or
highly severe) symptoms.
Eighty-nine patients (9.4%) reported side effects related
to the upper respiratory tract (Table 2). Asthma (23.6%) or
nose bleedings (21.3%) formed a large part of this group,
but most patients indicated other type of symptoms (39.3%)
in this category. Almost half of the number of these
patients had side effects for more than 2 years, but 30.1%
only experienced problems shorter than 3 months. The side
effects occurred less than once a week in half the number
of cases. In our study, severe asthma was reported to occur
in two patients, which, expressed as a proportion of all
respiratory patients, amounted to 3.5% (2 of 57). Side
effects considering the blood and lymphoid system were
relatively rare (4.4%). Skin problems occurred in 70 patients
(7.4%). In 38.6% of the cases, it concerned skin rash, but in
most cases these symptoms were classified as other skin
problems. Immune system side effects were very rare
(0.7%). Angio-oedema occurred in three patients.
The results for gastrointestinal-related side effects are
shown in Table 3. These side effects were experienced in
25.1% of the patients (238 of 947 patients). Heartburn was
reported most often (54.2%). Epigastric discomfort,
gastritis and epigastric pain occurred in 20% of the patients.
Nearly 40% of gastrointestinal side effects existed for more
than 2 years. Considering the frequency of side effect
occurrence, 61.0% of the patients experienced side effects
only seldom. The course of side effects over time was
stable. There was no difference in severity of gastrointes-
tinal side effects throughout the previous 3 months in more
than half the number of patients, and only 9.5% of patients
reported that their situation had worsened. There were
reports of mild gastrointestinal side effects in 52.6% of the
patient population. Twelve patients experienced severe
side effects. These patients suffered from gastrointestinal
bleeding (two patients), peptic ulcer (three patients) and
epigastric reflux/pain (seven patients).
Table 3 Characteristics of symptoms of ASA intolerance
in the gastrointestinal tract
Symptoms % n
Gastrointestinal tract 25.1% 238
Epigastric discomfort 20.2% 48
Epigastric pain 17.2% 41
Vomiting 2.5% 6
Constipation 4.6% 11
Diarrhoea 4.2% 10
Gastrointestinal bleeding 5.0% 12
Gastric ulcer 3.3% 8
Duodenal ulcer 4.6% 11
Epigastric burning/reflux 54.2% 129
Gastritis 19.3% 46
Other 18.1% 43
Period 217
0e4 weeks 14.3% 31
1e3 months 14.7% 32
3e6 months 10.6% 23
6e12 months 8.8% 19
1e2 years 12.0% 26
Over 2 years 39.6% 86
Missing 21
Frequency 218
Less than 10% of time 61.0% 133
More than 25% of time 28.0% 61
More than 50% of time 8.3% 18
Almost 100% of time 2.8% 6
Missing 20
Course 210
Improvement in the last 3 months 19.5% 41
Worsened in the last 3 months 9.5% 20
No difference in the last 3 months 52.4% 110
No symptoms in the last 3 months 18.6% 39
Missing 28
Severity 215
Mild 52.6% 113
Moderate 41.9% 90
Severe 5.6% 12
Missing 23
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This multicentre observational study in 947 patients who
were prescribed a low dose of ASA suggests that approxi-
mately 30% of this population shows at least one sign of ASA
intolerance. The most common side effects are associated
with the gastrointestinal tract. Although most patients
experienced mild symptoms, 5.6% of the patients with
gastrointestinal side effects considered them as severe. A
review of randomised controlled trials on the gastrointes-
tinal toxicity of aspirin revealed that the pooled odds ratio
(ORs) for categories of gastrointestinal bleeding were
between 1.5 and 2.0.8 The risk of peptic ulcer and upper
gastrointestinal symptoms was increased (ORs 1.3 and 1.7,
respectively). The review included mainly trials in which
a higher dose of ASA was used (over 500 mg per day). Itshowed that toxicity of ASA use was dose related. Previous
studies have demonstrated the benefit of a low dose of ASA
in the secondary prevention of atherothrombosis.1 Our
study quantifies signs of gastrointestinal side effects in
a population of patients prescribed a low dose of ASA. A
recent study demonstrated that endoscopy in asymptom-
atic patients using a low dose of ASA showed haemorrhagic
abnormalities in the duodenum or stomach in almost half
the number of cases.13 Although most patients with
gastrointestinal side effects considered them to be mild,
the clinical relevance of these symptoms becomes clear by
the fact that a quarter of the patients on ASA also used an
anti-acid agent. However, it remains unclear from our study
if such an agent (ASA of anti-acid agent) was given for
treatment or prevention.
In our study, 9.4% of the cases presented with side
effects of the upper respiratory tract, such as asthma
(23.6%). A large cohort study in Finland demonstrated that
the risk of aspirin intolerance causing shortness of breath or
asthma was 8.0 times higher in people with allergic rhinitis
than without.10 Bochenek et al.14 showed that atopy is
related to adverse drug reactions to NSAID. The mechanism
of aspirin-precipitated asthma is thought to be related to
the inhibition of cyclo-oxygenase (COX) and generation of
cysteinyl leukotrienes in the respiratory tract of sensitive
patients.15
In our patient population, 60 had discontinued ASA
treatment, more than half of them because of side effects.
Treatment cessation by the patient without prior medical
advice may be deleterious in patients at risk for athero-
thrombosis. In a meta-analysis, aspirin discontinuation or
non-compliance was associated with a threefold higher risk
of major cardiac events in patients with coronary artery
disease.11 This risk is even higher in patients with an
intracoronary stent. Other platelet aggregation inhibitors
have become available, with similar or even better results
concerning the secondary prevention of atherothrombotic
events.2,16 It is necessary that future studies focus on the
differences in side effects of these agents compared to
ASA. We could hypothesise that less intolerance with equal
or better efficacy may become a reason to favour a new
medicine over ASA in the secondary prevention of
atherothrombosis.
It can be assumed that doctors would screen their
patients for the presence of contraindications before
prescribing ASA. In our study, 13.7% of patients reported
gastric pain after previous use of ASA or a history of
stomach complaints (Table 1). In a study by Silagy et al.,6
the adverse effects of low-dose aspirin (100 mg daily) in the
elderly were studied over a 12-month period in a double-
blind, randomised, placeboecontrolled trial. In this study,
400 subjects were randomised to receive low-dose aspirin
(100 mg daily) or placebo. Gastrointestinal symptoms were
reported by 18% (nZ 36) of participants receiving aspirin
(compared to 13% in the placebo group). The relatively high
incidence may be due to the fact that the definition of the
gastric contraindication leaves room for a considerable
number of gastric clinical entities. However, if we look at
the contraindication ‘history of peptic ulcer disease or
gastrointestinal bleeding’ (7.1%), we can conclude that for
a well-defined entity such as peptic ulcer disease or
gastrointestinal bleeding, the reported incidence is still
602 E. Tournoij et al.7.1%. According to the prescribing information, these
patients should never have started ASA use.
The concomitant use of antacids, including proton pump
inhibitors, in this study was reported to be 25.0% (226 of 906
patients). Two studies have compared aspirin to clopidogrel
with antacid therapy. In the first study by Ng et al.17
patients with aspirin-induced peptic ulcer disease treated
with omeprazole (20 mg per day) were randomised to
receive clopidogrel (75 mg per day) or to continue with low-
dose aspirin. A minor gastrointestinal bleed was reported in
45% of the clopidogrel group and 42% of the aspirin group.
The distributions of peptic ulcer disease were similar in the
clopidogrel and aspirin groups. Using per protocol analysis,
the treatment success rates of clopidogrel and aspirin were
94% (62 of 66) and 95% (57 of 60), respectively.
A second study by Chan et al.18 compared clopidogrel
alone with aspirin plus esomeprazole on the prevention of
recurrent ulcer bleeding. The cumulative incidence of
recurrent bleeding during the 12-month period was 8.6%
(95% confidence interval (CI): 4.1e13.1%) among patients
who received clopidogrel and 0.7% (95% CI: 0e2.0%) among
those who received aspirin plus esomeprazole (difference:
7.9 percentage points; 95% CI for the difference: 3.4e12.4;
pZ 0.001). A third group receiving clopidogrel plus eso-
meprazole was not included in this study. Both studies had
great contributions to the knowledge about ASA treatment
in combination with a proton pump inhibitor. However, in
both studies, patients with known peptic ulcer disease or
gastric bleeding were included. On that aspect, patients in
those studies differed from our study population.
Our study has several limitations. First, to show that the
symptoms addressed by patients using ASA are specific for
ASA, it would be better to carry out a placeboecontrolled
trial. However, with a placeboecontrolled trial, the
patients in the placebo group would be withdrawn from
essential medication (i.e., ASA) needed to prevent them
from having a new atherothrombotic event. Placeboe
controlled trials studying ASA intolerance would place
patients potentially at risk and are, therefore, unethical.
The aim of the study was to explore the magnitude of the
occurrence of side effects of low-dose ASA in daily clinical
practice. Our study demonstrates that even a low dose of
ASA can induce symptoms suggestive of intolerance.
Second, we did not conduct detailed descriptions of
possible side effects of ASA. We mainly focussed on the
symptoms that were most prevalent in our population, and
further studies are needed to investigate the cause of these
side effects. Third, despite its use in clinical practice, the
ROME II criteria were developed to be used in epidemio-
logical studies and not designed for this purpose. Lastly,
there might be an additive effect of NSAID on the occur-
rence of side effects, which may increase the prevalence of
ASA intolerance beyond its strict magnitude. However, only
a relatively small part (6.6%) of the patients used ASA and
NSAID.
In conclusion, side effects of low-dose daily ASA occur in
a considerable number of patients. Patients and doctors
need to be aware of a possible relationship between their
symptoms and the use of ASA. This study shows that more
attention to the occurrence of side effects after prescribing
ASA may identify patients at risk. A proactive approach in
the collection of information about adverse effects may beof benefit, because the occurrence of side effects is the
most important reason for patients to discontinue ASA
treatment, with a possible increase in atherothrombotic
events. When adverse effects are suspected, doctors should
either (1) treat the symptoms, for example, by prescribing
antacids when gastrointestinal side effects occur or (2)
advise against the use of ASA and initiate another platelet
aggregation inhibitor.
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